ACS

2019 ANNUAL MEETING PROGRAM 


CLICK HERE FOR MEETING HOME

Utah Chapter of the American College of Surgeons

and

Utah Society of Anesthesiologists

Annual Meeting Program

*All times subject to change

This activity has been approved for 3.75 AMA PRA Category 1 CME Credits

 4:30pm – 6:30pm   Reception and Trainee Poster Competition (Cash prizes top 3 posters)
 
 6:30pm 6:45pm
 Chapter Announcements
 
 6:45pm – 8:00pm               
 Dinner and Keynote Speaker, Dr. Hance Clarke, University of Toronto

 8:00pm 9:00pm Panel Discussion--Strategies to Reduce Opioid Use and Achieve Optimal
 Pain Control Following Surgery 



Program Objectives

    • Provide a comprehensive educational/didactic overview of different strategies for reducing opioid use in the perioperative period.
    • Give attendants specific recommendation for non-opioid therapies that can be implemented into clinical practice. This will include behavioral-cognitive therapies that can be used for surgical patients to help with pain control.
    • Teach attendants about specific interventions that are designed to reduce incidence of chronic opioid use after surgery and improve patient’s functional recovery.
    • Provide education to health care providers that can be taken back to their own institutions and implemented into practice.

Disclosure Information

In accordance with the ACCME Accreditation Criteria, the American College of Surgeons, as the accredited provider of this activity, must ensure that anyone in a position to control the content of the educational activity has disclosed all relevant financial relationships with any commercial interest. Therefore, it is mandatory that both the program planning committee and speakers complete disclosure forms. The ACCME defines a ‘commercial interest’ as “any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients”.

The ACCME also requires that ACS manage any reported conflict and eliminate the potential for bias during the session. The planning committee members and speakers were contacted and the conflicts listed below have been managed to our satisfaction. However, if you perceive a bias during a session, please advise us of the circumstances on the session evaluation form.

Please note we have advised the speakers that it is their responsibility to disclose at the start of their presentation if they will be describing the use of a device, product, or drug that is not FDA approved or the off-label use of an approved device, product, or drug or unapproved usage.

The requirement for disclosure is not intended to imply any impropriety of such relationships, but simply to identify such relationships through full disclosure and to allow the audience to form its own judgments regarding the presentation.



Powered by Wild Apricot Membership Software